AAMDSIF Research Grants Program
For over 35 years, AAMDSIF has provided research grants totaling in excess of $6 million to an international group of 109 researchers to help advance the understanding and treatment of aplastic anemia
Myelodysplastic Syndromes (MDS)
Participate in Research
Patients can make a difference in the development of future treatments and the improvement of outcomes by participating in research. Check out the sections here to discover if any of these options are suitable for you.
Understanding Clinical Trials
Clinical research Clinical research: A type of research that involves individual persons or a group of people.
Advice for Caregivers
The National Family Caregivers Association's Director of Caregiver Wellness Programs, Jane Meier Hamilton, RN, MSN, has been a nurse for 40 years and family caregiver for 20 years. In a recent interview, she offered advice for family caregivers.
Is it true to say that many people don’t realize that they are caregivers?
Fundraise
Raising money for AAMDSIF through fundraising events also raises awareness for rare bone marrow failure bone marrow failure: A condition that
Ways to Give
Your financial donation is the best way to ensure patients get the support they need. There are several creative ways you can give.
Medical Research Basics
Learn about the process to bring new therapies and treatments to patients.
Here are explanations of why and how research is developed, the different types of research involved, and how registries are used to improve the lives of patients.
"Let's Roll:" What the Heroes of 9/11 can Teach us about Facing Blood Cancer
The morning of 9/11/01 was a doubly surreal experience for me. I was waiting for an appointment with my doctor at M. D. Anderson's Leukemia Center in Houston while chaos erupted in America. The waiting room was packed, as usual, with people at various stages of their own life-threatening events, and I was struck by the relative calm in this room compared to the state of disbelief and panic playing out on TVs throughout the country.
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the options for patients with lower risk (LR) MDS who have high transfusion needs and do not harbor ring sideroblasts or 5q- syndrome are limited. Here, we review the current treatment landscape in MDS and identify areas of unmet need, such as treatment after failure of erythropoiesis-stimulating agents or DNMTis, TP53-mutated disease, and MDS with potentially targetable mutations.